ECRM_1170x120_8-1-17

Earwax MD takes new approach to earwax impaction

Print Friendly, PDF & Email
DALLAS — Eosera Inc. is set to launch Earwax MD, which the company describes as a breakthrough over-the-counter remedy for earwax impaction.

A patent-pending topical drop, Earwax MD is a proprietary formula with a dual-action technology to dissolve earwax buildup. Eosera said the solution cuts through lipids and wax and disrupts the skin cells and debris that constitute earwax.

Earwax MD_contents_Eosera IncIn a clinical evaluation of people with moderate to severe earwax impaction, a single treatment of Earwax MD (up to two applications) fully cleared the impaction in 86% of test subjects, Eosera said. Earwax MD also reduced symptoms by 82%.  Common symptoms include a feeling of fullness, itching and hearing loss.

The product is slated to become available on April 1 at major chain drug stores and Amazon.com.

According to Eosera, earwax impaction affects about one in 10 children, one in 20 adults and one in three seniors, but many don’t seek treatment because of inconvenience, lack of knowledge and cost, among other reasons.

“Millions of people are suffering from ear pain and discomfort due to earwax impaction. Embarrassment mixes with frustration and despair as conventional store-bought solutions fail to solve the problem,” stated Elyse Stoltz Dickerson, co-founder and chief executive officer of Eosera. “With Earwax MD, there is finally a product that fulfills the promise to dissolve earwax quickly. Groundbreaking science has led to a product that will improve the lives of millions suffering from earwax impaction.”

Eosera noted that health care providers loathe earwax impaction nearly as much as their patients. For ear, nose and throat (ENT) specialists, earwax removal is time-consuming and unprofitable, and most would prefer that patients use an OTC solution, though they know that the options on pharmacy shelves are limited in efficacy. Family practice doctors and pediatricians often refer patients to ear specialists, while audiologists who choose to clear impactions usually lose money but do so to retain patients.

The combination of innovation backed by scientific evidence brought by Earwax MD has been lacking since the introduction of the earwax impaction product category more than 50 years ago, Eosera added.

“In short, everyone needed a modern solution to combat earwax impaction. Eosera has developed it,” commented Joe Griffin, co-founder and chief science officer at Eosera.


PIP-ROC_728x90

INNOV_728x90_8-1-17

Comments are closed.